Treatment and Control of Atopic Dermatitis With 0.03% Tacrolimus Ointment
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
A long-term 0.03% tacrolimus ointment based regimen comprising of up to 6 weeks of initial twice daily treatment and subsequent twice weekly prophylactic application can effectively treat active lesions of atopic dermatitis, and prevent, delay, and reduce flares.
Number of exacerbations of atopic dermatitis requiring intervention. [ Time Frame: 12 months ]
Secondary Outcome Measures
Time to first exacerbation requiring intervention; exacerbation treatment days, periods and time to first exacerbation; physician and patient assessment of affected area, treatment response; quality of life; global response. [ Time Frame: 12 months ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
2 Years to 15 Years (Child)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Male or female patient of any ethnic group
Patient was at least 2-15 years old and suffered from mild to severe atopic dermatitis (Rajka/Langeland score of at least 3)
Patient had a genetic epidermal barrier defect such as Netherton's syndrome or generalised erythroderma
Patient had a clinically significant skin infection on the affected (and to be treated) area